Research progress on western medicine first-line, traditional Chinese medicine combined with western medicine first-line in the treatment of extensive stage small cell lung cancer
LI Shumeng1 CHEN Yuyi2 WU Tongtong2 YU Mingwei2 YANG Guowang2
1.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China; 2.Department of Oncology, Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University, Beijing 100010, China
Abstract：This article summarizes clinical research on western medicine first-line, traditional Chinese medicine combined with western medicine first-line in the treatment of extensive stage small cell lung cancer in recent years. It is found that compared to the single first-line treatment of western medicine, the combination treatment of traditional Chinese medicine, characterized by differentiation of symptoms and treatment, has shown therapeutic advantages such as increasing efficacy, reducing toxicity, prolonging survival, improving traditional Chinese medicine symptoms, and enhancing immunity. It is suggested that traditional Chinese medicine should not only serve as a backup option for the failure of western medicine treatment, but should intervene as early as possible and participate throughout the entire process, forming a complementary traditional Chinese medicine combined treatment model with modern medical models, and achieving maximum benefits.
李姝蒙1 陈芋屹2 吴桐桐2 于明薇2 杨国旺2. 西医一线、中医药联合西医一线治疗广泛期小细胞肺癌的研究进展[J]. 中国医药导报, 2023, 20(30): 43-46.
LI Shumeng1 CHEN Yuyi2 WU Tongtong2 YU Mingwei2 YANG Guowang2. Research progress on western medicine first-line, traditional Chinese medicine combined with western medicine first-line in the treatment of extensive stage small cell lung cancer. 中国医药导报, 2023, 20(30): 43-46.
[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN estimates of incidence and mortality wor- ldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2021，71（3）：209-249. [2] Oronsky B，Reid TR，Oronsky A，et al. What’s new in SCLC? A review [J]. Neoplasia，2017，19（10）：842-847. [3] Farid S，Liu SV. Chemo-immunotherapy as first-line treatment for small-cell lung cancer [J]. Ther Adv Med Oncol，2020，12：1758835920980365. [4] Zugazagoitia J，Paz-Ares L. Extensive-stage small-cell lung cancer：first-line and second-line treatment options [J]. J Clin Oncol，2022，40（6）：671-680. [5] Yang S，Zhang Z，Wang Q. Emerging therapies for small cell lung cancer [J]. J Hematol Oncol，2019，12（1）：47. [6] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Small cell lung cancer，version3. 2023 [EB/OL]. https：//www.nccn.org/login?ReturnURL= https：//www.nccn.org/professionals/ phys ician_gls/pdf/sclc.pdf. [7] Horn L，Mansfield AS，Szcz?誰sna A，et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer [J]. N Engl J Med，2018，379（23）：2220-2229. [8] Nishio M，Sugawara S，Atagi S，et al. Subgroup analysis of Japanese patients in a phase Ⅲ study of atezolizumab in extensive-stage small-cell lung cancer（IMpower133） [J]. Clin Lung Cancer，2019，20（6）：469.e1-476.e1. [9] Mansfield AS，Ka■arnowicz A，Karaseva N，et al. Safety and patient-reported outcomes of atezolizumab，carboplatin，and etoposide in extensive-stage small-cell lung cancer（IMpower133）：a randomized phase Ⅰ/Ⅲ trial [J]. Ann Oncol，2020， 31（2）：310-317. [10] Paz-Ares L，Dvorkin M，Chen Y，et al. CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer （CASPIAN）：a randomised，contro- lled，open-label，phase 3 trial [J]. Lancet，2019，394（10212）：1929-1939. [11] Rudin CM，Awad MM，Navarro A，et al. KEYNOTE-604 Investigators. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer：randomized，double-blind，phase Ⅲ KEYNOTE- 604 study [J]. J Clin Oncol，2020，38（21）：2369-2379. [12] Leal T，Wang Y，Dowlati A，et al. Randomized phase Ⅱ clinical trial of cisplatin/carboplatin and etoposide （CE） alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer （ES-SCLC）：ECOGACRINEA5161 [J]. J Clin Oncol，2020，38（15）：9000. [13] Cheng Y，Han L，Wu L，et al. ASTRUM-005 Study Group. Effect of first-line serplulimab vs placebo added to chem- otherapy on survival in patients with extensive-stage small cell lung cancer：the ASTRUM-005 randomized clinical trial [J]. JAMA，2022，328（12）：1223-1232. [14] Wang J，Zhou C，Yao W，et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer （CAPSTONE-1）：a multic- entre，randomised，double-blind，placebo-controlled，phase 3 trial [J]. Lancet Oncol，2022，23（6）：739-747. [15] Lan CY，Zhao J，Yang F，et al. Anlotinib combined with TQB- 2450 in patients with platinum-resistant or refractory ovarian cancer：a multi-center，single-arm，phase 1b trial [J]. Cell Rep Med，2022，3（7）：100689. [16] Morgensztern D，Besse B，Greillier L，et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing，relapsed/refractory small- cell lung cancer：results from the phase Ⅱ TRINITY study [J]. Clin Cancer Res，2019，25（23）：6958-6966. [17] Cheng Y，Wang Q，Li K，et al. Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer：a randomised，double-blind，placebo-controlled phase 2 study [J]. Br J Cancer，2021，125（3）：366-371. [18] 徐梦圆，张俊文，苏延军，等.小细胞肺癌分子分型研究进展[J].中国肺癌杂志，2021，24（10）：734-738. [19] 沈云博，严博煜，刘枫，等.肺癌癌因性疲乏病因病机及中医药治疗的研究进展[J].中国医药导报，2023，20（6）：51-54. [20] 刘殿龙，侯炜.从痰、瘀辨证论治肺癌机制探讨[J].中华中医药杂志，2020，35（2）：783-785. [21] 孙焱，李灵常，李丹，等.霍介格教授从伏毒论治小细胞肺癌经验[J].浙江中医药大学学报，2020，44（2）：165- 169. [22] 关靓，周欢欢，王学谦，等.林洪生教授辨治小细胞肺癌经验[J].世界中医药，2020，15（8）：1187-1191. [23] 梁姗姗，李娜，张青.郁仁存治疗小细胞肺癌经验[J].中医杂志，2016，57（11）：913-915. [24] 韩丹，徐振晔，周卫东.徐振晔教授治疗小细胞肺癌经验[J].中国医药指南，2013，11（8）：615-616. [25] 亓润智，李丛煌，花宝金.花宝金治疗小细胞肺癌学术思想与经验探析[J].中华中医药杂志，2020，35（9）：4477- 4479. [26] 何姝霖，胡佳奇，刘瑞，等.花宝金教授“调气解毒”理论治疗小细胞肺癌脑转移经验[J].世界中医药，2023，18（1）：104-107. [27] 苏春雨，宋卓，徐竟男，等.健脾补肾法防治小细胞肺癌转移[J].中医学报，2016，31（5）：621-624. [28] 陈红，杨永，孙旭，等.抗癌解毒、化痰祛瘀治疗小细胞肺癌[J].中医杂志，2018，59（23）：2061-2063. [29] 余慧，刘庆，周溢鑫，等.中医药一线联合化疗治疗广泛期小细胞肺癌的Meta分析[J].中国处方药，2021，19（5）：133-136. [30] 介睿峥，刘怀民，孙旭，等.中医药干预治疗广泛期小细胞肺癌的回顾性队列研究[J].辽宁中医杂志，2022，49（11）：10-14，221. [31] 肖献辉，贾润苗，李红珂，等.艾灸足三里穴位治疗广泛期小细胞肺癌化疗后骨髓抑制疗效观察[J].中医药临床杂志，2019，31（2）：339-342. [32] 薛美平，刘丽坤，郭燕蓉，等.中医药维持治疗小细胞肺癌的临床研究[J].世界中西医结合杂志，2017，12（9）：1271-1274. [33] 温艳艳.康艾注射液联合盐酸伊立替康和卡铂治疗广泛期小细胞肺癌的临床疗效[J].临床研究，2020，28（5）：125-127. [34] Chen Y，Yu M，Liu Z，et al. Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival：study protocol of a multicenter，randomized，single- blind，placebo-controlled trial [J]. Trials，2021，22（1）：437. [35] 孙一丹.“扶正解毒祛瘀法”参与治疗小细胞肺癌的回顾性研究[D].天津：天津中医药大学，2021. [36] Shao Y，Zhu W，Da J，et al. Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer [J]. Onco Targets Ther，2017， 10：2675-2683. [37] 马萌.表观遗传定义的肿瘤微环境及其中医证本质[J].中华中医药杂志，2020，35（6）：2987-2994. [38] 周珍，张莹雯.中医中药在肺癌靶向治疗中研究进展[J].辽宁中医药大学学报，2018，20（9）：167-170. [39] 薛美平，刘丽坤，郭燕蓉，等.中医药维持治疗小细胞肺癌的临床研究[J].世界中西医结合杂志，2017，12（9）：1271-1274. [40] Liu R，He SL，Zhao YC，et al. Chinese herbal decoction based on syndrome differentiation as maintenance therapy in patients with extensive-stage small-cell lung cancer：an exploratory and small prospective cohort study [J]. Evid Based Complement Alternat Med，2015，2015：601067.
2023, Vol. 20 
京公网安备 11010502046598号